Spherics is developing a portfolio of innovative and proprietary oral pharmaceutical products. Through the 505(b)(2) NDA process for enhanced formulations of proven drugs, Spherics will independently advance its products in an accelerated and capital efficient manner. Spherics is also selectively partnering with pharmaceutical companies to enhance the therapeutic profiles of New Chemical Entities (NCE’s) and candidates for Life Cycle Management (LCM).